Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ascites in ovarian cancer: MicroRNA deregulations and their potential roles in ovarian carcinogenesis

L. Záveský, E. Jandáková, V. Weinberger, V. Hanzíková, O. Slanař, M. Kohoutová

. 2022 ; 33 (1) : 1-16. [pub] -

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019499

Ovarian cancer comprises the most lethal gynecologic malignancy and is accompanied by the high potential for the incidence of metastasis, recurrence and chemotherapy resistance, often associated with a formation of ascitic fluid. The differentially expressed ascites-derived microRNAs may be linked to ovarian carcinogenesis. The article focuses on a number of miRNAs that share a common expression pattern as determined by independent studies using ascites samples and with regard to their functions and outcomes in experimental and clinical investigations.Let-7b and miR-143 have featured as tumor suppressors in ovarian cancer, which is in line with data on other types of cancer. Although two miRNAs, i.e. miR-26a-5p and miR-145-5p, act principally as tumor suppressor miRNAs, they occasionally exhibit oncogenic roles. The performance of miR-95-3p, upregulated in ascites, is open to debate given the current lack of supportive data on ovarian cancer; however, data on other cancers indicates its probable oncogenic role. Different findings have been reported for miR-182-5p and miR-200c-3p; in addition to their presumed oncogenic roles, contrasting findings have indicated their ambivalent functions. Further research is required for the identification and evaluation of the potential of specific miRNAs in the diagnosis, prediction, treatment and outcomes of ovarian cancer patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019499
003      
CZ-PrNML
005      
20220804135716.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/CBM-210219 $2 doi
035    __
$a (PubMed)34511487
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Záveský, Luděk $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Prague, Czech Republic $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Prague, Czech Republic
245    10
$a Ascites in ovarian cancer: MicroRNA deregulations and their potential roles in ovarian carcinogenesis / $c L. Záveský, E. Jandáková, V. Weinberger, V. Hanzíková, O. Slanař, M. Kohoutová
520    9_
$a Ovarian cancer comprises the most lethal gynecologic malignancy and is accompanied by the high potential for the incidence of metastasis, recurrence and chemotherapy resistance, often associated with a formation of ascitic fluid. The differentially expressed ascites-derived microRNAs may be linked to ovarian carcinogenesis. The article focuses on a number of miRNAs that share a common expression pattern as determined by independent studies using ascites samples and with regard to their functions and outcomes in experimental and clinical investigations.Let-7b and miR-143 have featured as tumor suppressors in ovarian cancer, which is in line with data on other types of cancer. Although two miRNAs, i.e. miR-26a-5p and miR-145-5p, act principally as tumor suppressor miRNAs, they occasionally exhibit oncogenic roles. The performance of miR-95-3p, upregulated in ascites, is open to debate given the current lack of supportive data on ovarian cancer; however, data on other cancers indicates its probable oncogenic role. Different findings have been reported for miR-182-5p and miR-200c-3p; in addition to their presumed oncogenic roles, contrasting findings have indicated their ambivalent functions. Further research is required for the identification and evaluation of the potential of specific miRNAs in the diagnosis, prediction, treatment and outcomes of ovarian cancer patients.
650    _2
$a ascites $x genetika $7 D001201
650    _2
$a karcinogeneze $x genetika $7 D063646
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a tumor supresorové geny $7 D016147
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $x genetika $x metabolismus $7 D035683
650    12
$a nádory vaječníků $x patologie $7 D010051
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Jandáková, Eva $u Department of Pathology, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Weinberger, Vít $u Department of Obstetrics and Gynecology, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Hanzíková, Veronika $u Faculty Transfusion Center, General University Hospital, Prague, Czech Republic
700    1_
$a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Kohoutová, Milada $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Prague, Czech Republic
773    0_
$w MED00173146 $t Cancer biomarkers : section A of Disease markers $x 1875-8592 $g Roč. 33, č. 1 (2022), s. 1-16
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34511487 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135710 $b ABA008
999    __
$a ok $b bmc $g 1822903 $s 1170742
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 33 $c 1 $d 1-16 $e - $i 1875-8592 $m Disease markers. Section A, Cancer Biomarkers $n Cancer Biomark $x MED00173146
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace